Baxter International Inc
BAX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$64.00 | Zswcmrn | Wfjkhykk |
Baxter Earnings: Strong Underlying Trends Boost 2024 Outlook Further
Narrow-moat Baxter turned in strong second-quarter results, and management raised its 2024 outlook on those trends. However, slightly higher near-term expectations do not materially change our $67 fair value estimate. Shares remain steeply undervalued, in our opinion, especially in a rising medical utilization and cooling inflationary environment that looks likely to continue boosting Baxter's profitability in the intermediate term.